| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?
|
Hamilton, Fergus
|
|
|
9 |
7 |
p. 687-689
|
article
|
| 2 |
2021 American Thoracic Society International Conference
|
Venkatesan, Priya
|
|
|
9 |
7 |
p. e65-e66
|
article
|
| 3 |
An integrated understanding of long-term sequelae after acute COVID-19
|
Olliaro, Piero L
|
|
|
9 |
7 |
p. 679-680
|
article
|
| 4 |
Balancing the needs of the many and the few: where next for adult asthma guidelines?
|
Shaw, Dominick E
|
|
|
9 |
7 |
p. 786-794
|
article
|
| 5 |
Bhutan: small nation, big ideas affecting respiratory health
|
Samarasekera, Udani
|
|
|
9 |
7 |
p. e67-e68
|
article
|
| 6 |
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK
|
Docherty, Annemarie B
|
|
|
9 |
7 |
p. 773-785
|
article
|
| 7 |
Combination CFTR modulator therapy in children and adults with cystic fibrosis
|
Guimbellot, Jennifer S
|
|
|
9 |
7 |
p. 677-679
|
article
|
| 8 |
Correction to Lancet Respir Med 2021; 9: 373–86
|
|
|
|
9 |
7 |
p. e62
|
article
|
| 9 |
Correction to Lancet Respir Med 2021; published online April 19. https://doi.org/10.1016/S2213-2600(21)00096-5
|
|
|
|
9 |
7 |
p. e62
|
article
|
| 10 |
Correction to Lancet Respir Med 2021; published online May 14. https://doi.org/10.1016/S2213-2600(21)00177-6
|
|
|
|
9 |
7 |
p. e62
|
article
|
| 11 |
COVID-19 and inhaled corticosteroids—another piece in an expanding puzzle
|
Schultze, Anna
|
|
|
9 |
7 |
p. 674-675
|
article
|
| 12 |
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion
|
van de Veerdonk, Frank L
|
|
|
9 |
7 |
p. 795-802
|
article
|
| 13 |
Cytokine adsorption during ECMO for COVID-19-related ARDS
|
Shekar, Kiran
|
|
|
9 |
7 |
p. 680-682
|
article
|
| 14 |
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial
|
Supady, Alexander
|
|
|
9 |
7 |
p. 755-762
|
article
|
| 15 |
Digital health: balancing innovation and cybersecurity
|
The Lancet Respiratory Medicine,
|
|
|
9 |
7 |
p. 673
|
article
|
| 16 |
Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
|
Agusti, Alvar
|
|
|
9 |
7 |
p. 682-683
|
article
|
| 17 |
Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?
|
Burki, Talha Khan
|
|
|
9 |
7 |
p. e64
|
article
|
| 18 |
From lockdown to vaccines: challenges and response in Nepal during the COVID-19 pandemic
|
Kansakar, Sajog
|
|
|
9 |
7 |
p. 694-695
|
article
|
| 19 |
How the light gets in
|
Thorley, Jennifer
|
|
|
9 |
7 |
p. 692
|
article
|
| 20 |
Inhaled budesonide for early treatment of COVID-19
|
San-Juan, Rafael
|
|
|
9 |
7 |
p. e58
|
article
|
| 21 |
Inhaled budesonide for early treatment of COVID-19
|
Zeitlinger, Markus
|
|
|
9 |
7 |
p. e59
|
article
|
| 22 |
Inhaled budesonide for early treatment of COVID-19
|
Choi, Jae Chol
|
|
|
9 |
7 |
p. e60
|
article
|
| 23 |
Inhaled budesonide for early treatment of COVID-19 – Authors' reply
|
Ramakrishnan, Sanjay
|
|
|
9 |
7 |
p. e61
|
article
|
| 24 |
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|
Ramakrishnan, Sanjay
|
|
|
9 |
7 |
p. 763-772
|
article
|
| 25 |
Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
|
Chilvers, Mark A
|
|
|
9 |
7 |
p. 721-732
|
article
|
| 26 |
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
|
Flume, Patrick A
|
|
|
9 |
7 |
p. 733-746
|
article
|
| 27 |
Misdiagnosis of sarcoidosis
|
Morgan, Jules
|
|
|
9 |
7 |
p. 696-698
|
article
|
| 28 |
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study
|
Wu, Xiaojun
|
|
|
9 |
7 |
p. 747-754
|
article
|
| 29 |
Passive tobacco smoke in children and young people during the COVID-19 pandemic
|
Osinibi, Mira
|
|
|
9 |
7 |
p. 693-694
|
article
|
| 30 |
Perplexing mortality data from triple therapy trials in COPD
|
Suissa, Samy
|
|
|
9 |
7 |
p. 684-685
|
article
|
| 31 |
Repurposing drugs for treatment of COVID-19
|
Venkatesan, Priya
|
|
|
9 |
7 |
p. e63
|
article
|
| 32 |
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK
|
Bloom, Chloe I
|
|
|
9 |
7 |
p. 699-711
|
article
|
| 33 |
SARS-CoV-2 antigen testing: weighing the false positives against the costs of failing to control transmission
|
Fearon, Elizabeth
|
|
|
9 |
7 |
p. 685-687
|
article
|
| 34 |
SARS-CoV-2 reinfection in a closed setting: lessons for the community
|
Velasco, María
|
|
|
9 |
7 |
p. 675-677
|
article
|
| 35 |
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
|
Letizia, Andrew G
|
|
|
9 |
7 |
p. 712-720
|
article
|
| 36 |
The 2021 USPSTF lung cancer screening guidelines: a new frontier
|
Potter, Alexandra L
|
|
|
9 |
7 |
p. 689-691
|
article
|
| 37 |
Viable virus shedding during SARS-CoV-2 reinfection
|
Letizia, Andrew G
|
|
|
9 |
7 |
p. e56-e57
|
article
|
Journal description